BioNexus Gene Lab Becomes First Nasdaq-Listed Company to Adopt Ethereum as Treasury Asset

BioNexus Gene Lab Corp., a healthcare technology company based in Wyoming, has made history by becoming the first Nasdaq-listed firm to adopt Ethereum (ETH) as its primary treasury asset. This decision, announced on March 5, is backed by a strategic whitepaper that outlines the advantages of Ethereum over Bitcoin (BTC). BioNexus emphasizes Ethereum's flexibility, liquidity, and stability, citing its increasing institutional acceptance and use in decentralized finance (DeFi). Despite a recent decline in ETH's market performance, the company's shift aims to position BioNexus as a leader in blockchain-integrated corporate finance and adds weight to ongoing discussions about corporate adoption of digital assets. The announcement follows conversations around Ethereum's scalability and upcoming upgrades. However, ETH has seen significant outflows from ETFs recently, raising concerns about its immediate price stability.